Esophageal small cell carcinomas - Clinicopathologic parameters, p53 overexpression, proliferation marker, and their impact on pathogenesis

Objective.-To evaluate the clinicopathologic features and the roles of p53 and MIB-1 in esophageal small cell carcinoma. Method.-Twenty patients (14 men and 6 women) with esophageal small cell car cinoma treated in our hospital from 1982 through 1996 were studied. The cli nicopathologic features, treatment received, and survival data of these pat ients were documented. Representative tissue was collected from each tumor, and immunohistochemical preparations for p53 protein and MIB-1 were made. Results.-Small cell carcinoma accounted for 1.3% of all esophageal malignan t tumors. The median age of patients at presentation was 60 years. On gross examination, the tumors were large ulcerative lesions (median length, 7.5 cm). In 17 patients in whom p53 immunohistochemical study was performed, p5 3 protein was detected in 65% (9 of 17). All stage IV tumors were negative for p53 expression. The median tumor cell MIB-1 score was high at 855 (rang e, 810-964) positive cells per 1000. Overall median survival was 3.4 months . In patients who underwent chemotherapy, there was significant response. Conclusions.-Esophageal small cell carcinoma is an aggressive tumor. Overex pression of p53 is associated with early stages of carcinogenesis. The high proliferative index, as defined by the MIB-1 immunohistochemical method, m ay be related to aggressive behavior and high sensitivity to chemotherapy a nd radiotherapy.